EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms

Kelly S Chien iD, Faustine Ong, Kunhwa Kim iD, Ziyi Li, Rashmi Kanagal-Shamanna iD, Courtney D DiNardo iD, Koichi Takahashi, Guillermo Montalban-Bravo iD, Danielle Hammond, Koji Sasaki, Sherry A Pierce, Hagop M Kantarjian iD und 1 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kelly S Chien und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Neoplasms, Myeloproliferative Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The occurrence of somatic mutations in patients with no evidence of hematological disorders is called clonal hematopoiesis (CH). CH, whose subtypes include CH of indeterminate potential and clonal cytopenia of undetermined significance, has been associated with both hematologic cancers and systemic comorbidities. However, CH's effect on patients, especially those with concomitant malignancies, is not fully understood.

Methods

We performed a retrospective evaluation of all patients with CH at a tertiary cancer center. Patient characteristics, mutational data, and outcomes were collected and analyzed.

Results

Of 78 individuals included, 59 (76%) had a history of cancer and 60 (77%) had moderate to severe comorbidity burdens. DNMT3A , TET2 , TP53 , and ASXL1 were the most common mutations. For the entire cohort, the 2‐year overall survival rate was 79% (95% CI: 70, 90), while the median survival was not reached. Of 20 observed deaths, most were related to primary malignancies ( n = 7, 35%), comorbidities ( n = 4, 20%), or myeloid neoplasms ( n = 4, 20%). Twelve patients (15%) experienced transformation to a myeloid neoplasm. According to the clonal hematopoiesis risk score, the 3‐year transformation rate was 0% in low‐risk, 15% in intermediate‐risk ( p = 0.098), and 28% in high‐risk ( p = 0.05) patients. By multivariate analysis, transformation was associated with variant allele frequency ≥0.2 and hemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMyeloproliferative DisordersHumansClonal HematopoiesisRetrospective StudiesHematopoiesisComorbidity

Stichwörter der Autor:innen

CCUSCHIPclonal cytopenia of undetermined significanceclonal hematopoiesisclonal hematopoiesis of indeterminate potential

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Kelly S Chien, Kunhwa Kim, Rashmi Kanagal-Shamanna, Courtney D DiNardo, Guillermo Montalban-Bravo, Hagop M Kantarjian

Förderung

  • NCI NIH HHS
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Chien, K. S., Ong, F., Kim, K., Li, Z., Kanagal-Shamanna, R., DiNardo, C. D., Takahashi, K., Montalban-Bravo, G., Hammond, D., Sasaki, K., Pierce, S. A., Kantarjian, H. M., & Garcia-Manero, G. (2024). Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Medicine. https://doi.org/10.1002/cam4.7093

Vancouver

Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, et al. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Medicine. 2024. doi:10.1002/cam4.7093

BibTeX
@article{Chien2024,
  author = {Chien, Kelly S and Ong, Faustine and Kim, Kunhwa and Li, Ziyi and Kanagal-Shamanna, Rashmi and DiNardo, Courtney D and Takahashi, Koichi and Montalban-Bravo, Guillermo and Hammond, Danielle and Sasaki, Koji and Pierce, Sherry A and Kantarjian, Hagop M and Garcia-Manero, Guillermo},
  title = {Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7093}
}
Kostenlos starten →